Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Sarcoma 1Nasopharyngeal Carcinoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Hepatocellular 1Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy 1

Interventions

Cisplatin 4pembrolizumab 3Nivolumab 3Fluorouracil 2Carboplatin 2toripalimab 1spartalizumab 1fludarabine phosphate 1fludarabine 1cc-486 1camrelizumab 1Vorinostat 1Valganciclovir 1Range of Motion, Articular 1Radiotherapy 1Radiosurgery 1Protons 1Platinum 1Methylprednisolone 1Medicare Part B 1Laryngoscopes 1Gemcitabine 1Docetaxel 1Cyclophosphamide 1Cetuximab 1Bevacizumab 1Azacitidine 1Adrenal Cortex Hormones 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Nasopharyngeal Carcinoma × toripalimab × Clear all
NCT03474640 2024-11-22

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

TopAlliance Biosciences

Phase 1 Completed
184 enrolled 20 charts
GastrointestinalHead & NeckSarcoma

Nasopharyngeal Carcinoma, Chondrosarcoma, Esophageal Neoplasms, Carcinoma, Hepatocellular, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡